Benzodiazepine Derivative Multi-Target Ligand Neurodegeneration
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and neuropathic pain are inadequate, with existing medications providing temporary relief but not preventing disease progression, and are complicated by multiple-drug regimens that are challenging for elderly patients and caregivers due to pharmacokinetic and pharmacodynamic interactions.
Innovation Solution
Development of a multi-target-directed ligand, JM-20, a benzodiazepine derivative that acts on multiple pharmacological targets, potentially offering improved efficacy and safety by simplifying therapeutic regimens and reducing drug interactions, which can be administered in various forms including tablets, solutions, and transdermal patches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple drugs are administered to treat neurodegenerative diseases, then therapeutic coverage is improved, but treatment complexity and drug interactions increase
Solution Approach 1:
The patent combines multiple therapeutic functions into a single multi-target-directed ligand (MTDL) that can simultaneously act on multiple pharmacological targets (e.g., acetylcholinesterase, butyrylcholinesterase, NMDA receptors, mitochondrial complex I). This merging approach maintains comprehensive therapeutic coverage while eliminating the complexity of administering multiple separate drugs and avoiding drug-drug interactions.
Solution Approach 2:
The invention creates a universal compound with multi-functional activity that can treat multiple aspects of neurodegenerative diseases simultaneously. The MTDL is designed to interact with multiple targets involved in disease pathogenesis, providing broad therapeutic coverage through a single agent rather than requiring multiple specialized drugs.
2Reliability
If multiple drugs are administered to treat neurodegenerative diseases, then therapeutic coverage is improved, but pharmacokinetic and pharmacodynamic interactions increase
Solution Approach 1:
By merging multiple therapeutic functions into a single compound, the patent eliminates pharmacokinetic interactions (absorption, distribution, metabolism, excretion between drugs) and pharmacodynamic interactions (additive or synergistic effects between drugs) that would occur with multiple medication regimens.
3Ease of operation
If simplified treatment regimens are used, then compliance is improved, but therapeutic coverage may be reduced
Solution Approach 1:
The multi-target-directed ligand provides simplified treatment (single drug regimen) while maintaining comprehensive therapeutic coverage by acting on multiple disease-relevant targets simultaneously, thus resolving the trade-off between compliance and effectiveness.
Data Source
Figure 1~2
Figure 3~5
Figure 6
AI summary
Formula III compound, its products and pharmaceutical compositions containing them for the treatment of central nervous and vascular system diseases, particularly neurodegenerative disorders with cognitive deterioration, diseases associated with oxidative stress, diseases taking in mitochondrial dysfunction, Parkinson's disease and neuropathic pain, as well as the pathological processes associated with aging.